Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Merz

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 2, 2018
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting CellsChristian Merz, Jaromir Sykora, Viola Marschall, et al.
Molecular Cancer Therapeutics|October 9, 2013
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptorsChristian Gieffers, Michael Kluge, Christian Merz, et al.
Frontiers in Oncology|October 10, 2018
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor ImmunityMeinolf Thiemann, David M Richards, Karl Heinonen, et al.
Journal for Immunotherapy of Cancer|July 21, 2019
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionalityDavid M Richards, Viola Marschall, Katharina Billian-Frey, et al.
Frontiers in Immunology|June 12, 2023
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapyJamie Frankish, Debayan Mukherjee, Erminia Romano, et al.
Nature Cell Biology|April 27, 2010
Wnt activity defines colon cancer stem cells and is regulated by the microenvironmentLouis Vermeulen, Felipe De Sousa E Melo, Maartje van der Heijden, et al.
Annals of Hematology|February 27, 2024
Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic NeoplasmsAlexander Streuer, Johann-Christoph Jann, Tobias Boch, et al.
Nature Communications|August 21, 2025
The bispecific innate cell engager AFM28 eliminates CD123<sup>+</sup> leukemic stem and progenitor cells in AML and MDSNanni Schmitt, Jana-Julia Siegler, Alexandra Beck, et al.
Molecular Cancer Research : MCR|February 18, 2018
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for GlioblastomaJonas Blaes, Carina M Thomé, Philipp-Niclas Pfenning, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 2, 2018
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting CellsChristian Merz, Jaromir Sykora, Viola Marschall, et al.
Molecular Cancer Therapeutics|October 9, 2013
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptorsChristian Gieffers, Michael Kluge, Christian Merz, et al.
Frontiers in Oncology|October 10, 2018
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor ImmunityMeinolf Thiemann, David M Richards, Karl Heinonen, et al.
Journal for Immunotherapy of Cancer|July 21, 2019
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionalityDavid M Richards, Viola Marschall, Katharina Billian-Frey, et al.
Frontiers in Immunology|June 12, 2023
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapyJamie Frankish, Debayan Mukherjee, Erminia Romano, et al.
Nature Cell Biology|April 27, 2010
Wnt activity defines colon cancer stem cells and is regulated by the microenvironmentLouis Vermeulen, Felipe De Sousa E Melo, Maartje van der Heijden, et al.
Annals of Hematology|February 27, 2024
Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic NeoplasmsAlexander Streuer, Johann-Christoph Jann, Tobias Boch, et al.
Nature Communications|August 21, 2025
The bispecific innate cell engager AFM28 eliminates CD123<sup>+</sup> leukemic stem and progenitor cells in AML and MDSNanni Schmitt, Jana-Julia Siegler, Alexandra Beck, et al.
Molecular Cancer Research : MCR|February 18, 2018
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for GlioblastomaJonas Blaes, Carina M Thomé, Philipp-Niclas Pfenning, et al.
Pageof 3